secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2025-06-27T23:59:59+00:00
Accession:  0001683168-25-004784
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical FY2025 op loss $9.3M (down 26% YoY); Hemopurifier cancer trial treats first 3 patients
--------------------------------------------------------------------------------

- Cash balance $5.5M as of March 31, 2025; operating expenses $9.3M for FY2025, down 26% from $12.6M.
- First three patients treated in Hemopurifier cancer trial in Australia; DSMB safety review triggered.
- Received Indian regulatory approval (CDSCO) to initiate similar oncology trial at Medanta Medicity Hospital.
- Preclinical study showed 98.5% removal of platelet-derived EVs in simulated Hemopurifier treatment.
- Non-cash warrant inducement charge of $4.6M; ERTC other income $324,450.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316825004784/0001683168-25-004784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316825004784/aemd_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-004784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer